Surgery Partners stock (US85701Q1031): Earnings date in focus ahead of August report
Surgery Partners (SGRY) is expected to report its second-quarter earnings on August 4, 2026. The company, which operates ambulatory surgery centers, is watched by investors for its sensitivity to outpatient procedure volumes and reimbursement trends in the US healthcare market. The upcoming report will be crucial for insights into same-center performance, reimbursement, and demand for elective procedures.
Surgery Partners Inc stock (US85701Q1031): earnings momentum and M&A reshape outlook
Surgery Partners Inc (SGRY) recently reported strong quarterly results, driven by increased surgical case volumes and successful integration of past acquisitions within the US outpatient surgery market. The company is strategically focused on shifting procedures from inpatient to outpatient settings, capitalizing on favorable demographic trends and expanding into higher-acuity procedures like orthopedics and cardiology. Future performance hinges on continued case migration, effective acquisition integration, and managing regulatory and reimbursement changes in the evolving healthcare landscape.
[SCHEDULE 13G/A] Surgery Partners, Inc. Amended Passive Investment Disclosure
Pentwater Capital Management has filed an amended Schedule 13G/A, disclosing beneficial ownership of 12,655,000 shares of Surgery Partners, Inc. (SGRY), which represents 9.7% of the company's common stock. The filing indicates a passive investment intent with shared voting and dispositive power. Matthew Halbower is identified as a reporting person through his role with the Investment Manager.
Surgery Partners Delivered Solid Q1 Beat Amid Stabilizing Portfolio, RBC Says
RBC Capital Markets highlighted Surgery Partners' strong first-quarter performance, noting a solid beat on earnings and a stabilizing portfolio. The company is reportedly making progress in addressing its physician staffing needs, which is expected to support future growth. RBC reiterated an Outperform rating, increasing the price target to $46.
A Look At Surgery Partners (SGRY) Valuation After Reaffirmed Guidance And Positive First Quarter Results
Surgery Partners (SGRY) recently reported strong Q1 results, with revenue growth and a narrower loss, while reaffirming full-year guidance. Despite negative long-term share returns, the company is seen as potentially undervalued, trading at a discount to analyst targets. The stock's valuation hinges on continued margin expansion, revenue growth, and effective execution of M&A and portfolio optimization strategies.
Stronger Q1 Results And Reaffirmed Outlook Might Change The Case For Investing In Surgery Partners (SGRY)
Surgery Partners (SGRY) reported stronger-than-expected Q1 2026 results with narrower net losses and reaffirmed full-year revenue guidance, despite a significant debt load. The company's investment narrative continues to hinge on sustained outpatient surgery growth and operational execution to manage costs and achieve profitability targets. This performance may influence analyst forecasts, which currently vary widely on the company's long-term earnings potential.
Number of shareholders of Surgery Partners, Inc. – LSX:A14YWP
This article provides details about the number of shareholders for Surgery Partners, Inc. (LSX:A14YWP) on TradingView. It indicates that specific shareholder data is available for a given period, along with change values and percentages. The content is primarily a data placeholder within the TradingView platform, noting market and reference data sources.
Surgery Partners outlines 2026 revenue of $3.35B-$3.45B and adjusted EBITDA of at least $530M as portfolio optimization targets mid-2026 announcement
Surgery Partners (NASDAQ:SGRY) has provided its financial outlook for 2026, projecting revenue between $3.35 billion and $3.45 billion and adjusted EBITDA of at least $530 million. The company is actively engaged in a portfolio optimization strategy, with an update expected by mid-2026, aimed at enhancing financial performance and strategic alignment. These targets highlight the company's growth trajectory and efforts to streamline its operations for future profitability.
Stronger Q1 Results And Reaffirmed Outlook Might Change The Case For Investing In Surgery Partners (SGRY)
Surgery Partners (SGRY) recently reported stronger-than-expected first-quarter results, with revenue rising to US$810.9 million and a narrowing net loss. The company reaffirmed its full-year 2026 revenue guidance of US$3.35 billion to US$3.45 billion, despite its US$3.70 billion debt load. While the improved adjusted earnings and reaffirmed guidance are positive signals, the long-term investment narrative still hinges on balancing revenue growth from outpatient surgeries against persistent losses and high interest costs.
Surgery Partners price target raised to $17 from $15 at Jefferies
Jefferies has increased its price target for Surgery Partners (SGRY) to $17 from $15, maintaining a Buy rating. The adjustment follows the company's strong first-quarter performance, which occurred despite weather-related challenges affecting healthcare providers. Jefferies anticipates a gradual improvement in payor mix issues throughout the year.
FMR LLC holds 2.19M SGRY shares (1.7%) — Surgery Partners (NYSE: SGRY)
FMR LLC has filed a Schedule 13G/A amendment, reporting beneficial ownership of 2,191,465.08 shares of Surgery Partners (SGRY), which represents 1.7% of the company's common stock. The filing indicates that FMR LLC holds sole dispositive power over these shares, with Abigail P. Johnson also mentioned in related disclosures. This update provides transparency on significant holdings by large investors in Surgery Partners.
Surgery Partners Q1 2026 Earnings Call Transcript
Surgery Partners reported Q1 2026 net revenue of $811 million and adjusted EBITDA of $102 million, aligning with expectations despite weather-related disruptions impacting case growth. The company is reiterating its full-year 2026 guidance, focusing on organic growth through higher acuity procedures, strategic capital deployment for M&A, and portfolio optimization. Management emphasized cost control and improving cash flow, with a significant portfolio transaction anticipated mid-year.
Short-stay surgery operator keeps 2026 forecast after $811M quarter
Surgery Partners (NASDAQ:SGRY) announced its first quarter 2026 results, reporting revenue of $810.9 million, a 4.5% increase year-over-year, and reaffirming its full-year 2026 guidance for revenue between $3.35 billion and $3.45 billion and adjusted EBITDA of at least $530 million. Despite a net loss attributable to the company of $35.9 million, leadership expressed confidence in meeting growth targets through cost management, physician recruitment, and portfolio optimization. The company maintained a solid liquidity position with $182.3 million in cash and equivalents and $666.1 million in revolving credit capacity.
Surgery Partners (SGRY) Losses Of US$77.9 Million Keep Profitability Narrative Under Pressure
Surgery Partners (SGRY) reported Q4 2025 revenue of US$885 million and a net loss of US$15 million, with trailing 12-month losses reaching US$77.9 million. While revenue is growing, profitability remains a challenge, putting pressure on the company's narrative for investors. Analysts' projections for future profitability rely heavily on significant margin improvements and sustained revenue growth, which are yet to fully materialize.
Surgery Partners outlines 2026 revenue of $3.35B-$3.45B and adjusted EBITDA of at least $530M as portfolio optimization targets mid-2026 announcement
Surgery Partners (SGRY) has announced its financial targets for 2026, projecting revenue between $3.35 billion and $3.45 billion and adjusted EBITDA of at least $530 million. These targets coincide with a portfolio optimization strategy aimed at generating approximately $250 million from asset sales by mid-2026. The company anticipates utilizing these proceeds to pay down debt, furthering its financial goals.
Surgery Partners (SGRY) Q1 2026 revenue rises as net loss narrows
Surgery Partners (SGRY) reported a Q1 2026 revenue increase to $810.9 million from $776.0 million in Q1 2025, driven by a 4.4% rise in days adjusted same-facility revenue. The company also narrowed its net loss to $35.9 million in Q1 2026 from $37.7 million in the prior year, though Adjusted EBITDA slightly decreased to $102.3 million due to higher costs and interest expenses. Surgery Partners maintains substantial debt ($3.7 billion) but has strong liquidity with $182.3 million in cash and $666.1 million available on its credit facility, alongside a new $200 million share repurchase authorization.
Surgery Partners | 8-K: SURGERY PARTNERS, INC. ANNOUNCES FIRST QUARTER 2026 RESULTS REAFFIRMS FULL YEAR 2026 GUIDANCE
Surgery Partners, Inc. announced its financial results for the first quarter of 2026, reaffirming its full-year 2026 guidance. The company's 8-K filing detailed its performance and outlook for the fiscal year. This release provides key financial updates for investors and stakeholders.
Surgery Partners Narrows Slips to a Loss in Q1 2026, Beats Estimates
Surgery Partners, Inc. (NASDAQ: SGRY) reported a Q1 2026 adjusted loss of $0.03 per share, significantly narrower than the expected loss of $0.12 per share, and revenue of $810.9 million, a 4.5% increase from the previous year. The company demonstrated strong organic growth with a 4.4% increase in same-facility revenue. Despite beating estimates, the stock's market reaction was muted, likely due to the continued net loss and the absence of updated profitability guidance.
Surgery Partners: Q1 Earnings Snapshot
Surgery Partners Inc. (SGRY) reported a first-quarter loss of $35.9 million, or 28 cents per share, which adjusted to 3 cents per share for non-recurring costs and stock options, exceeded Wall Street expectations. The company also surpassed revenue forecasts, posting $810.9 million against an expected $798.8 million, and provided a full-year revenue outlook between $3.35 billion and $3.45 billion.
Surgery Partners Inc has recently announced that its financial outlook for fiscal year 2026 remains stable.
Surgery Partners Inc. has reaffirmed its financial outlook for fiscal year 2026, with total revenue projected to be between $3.35 billion and $3.45 billion and adjusted EBITDA expected to reach at least $530 million. This demonstrates management's confidence in the company's growth and profitability amidst changes in the healthcare industry. The clear guidance aims to help investors assess operational resilience and future value.
Surgery Partners posts Q1 revenue $810.9M, Adjusted EBITDA $102.3M; reaffirms 2026 guidance
Surgery Partners (SGRY) reported Q1 2026 revenue of $810.9 million and Adjusted EBITDA of $102.3 million. Despite a net loss of $35.9 million, same-facility revenues increased by 4.4% year-over-year. The company reaffirmed its full-year 2026 guidance, projecting revenues between $3.35–$3.45 billion and Adjusted EBITDA of at least $530 million.
Revenue up 4.5% as Surgery Partners (SGRY) reaffirms 2026 guidance
Surgery Partners (SGRY) reported a 4.5% increase in Q1 2026 revenue, reaching $810.9 million, driven by strong same-facility growth. Despite a slight dip in Adjusted EBITDA to $102.3 million from $103.9 million in the prior year, the company reaffirmed its full-year 2026 guidance, expecting revenues between $3.35 billion and $3.45 billion and Adjusted EBITDA of at least $530 million. Management expressed confidence in achieving growth targets through cost management, physician recruitment, and portfolio optimization amidst current market dynamics.
Surgery Partners: Q1 Earnings Snapshot
Surgery Partners Inc. (SGRY) reported a Q1 loss of $35.9 million, or 28 cents per share, which adjusted to 3 cents per share for non-recurring costs. These results surpassed Wall Street expectations, with revenue of $810.9 million also beating analyst forecasts. The company projects full-year revenue to be between $3.35 billion and $3.45 billion.
Surgery Partners: Q1 Earnings Snapshot
Surgery Partners Inc. (SGRY) reported a Q1 loss of $35.9 million, or 28 cents per share, which was 3 cents per share adjusted for non-recurring costs and stock option expenses. This result exceeded Wall Street expectations, as analysts had projected a loss of 15 cents per share. The company's revenue of $810.9 million also surpassed forecasts, and Surgery Partners anticipates full-year revenue between $3.35 billion and $3.45 billion.
Surgery Partners faces earnings test amid margin, volume concerns
Surgery Partners (SGRY) is facing an earnings test, with analysts predicting a Q1 loss of 12 cents per share and an 11% sequential revenue decline, contrasting with the prior quarter's profit. Investors will be closely watching volume trends, margin performance, and capital allocation decisions, especially given activist investor pressure and concerns about weaker physician hiring data compared to peers. The company's prior quarter missed EPS expectations, making the upcoming report crucial for assessing its recovery from 2025 headwinds.
How Surgery Partners Inc. (SGRY) Affects Rotational Strategy Timing
This article analyzes Surgery Partners Inc. (SGRY) and its impact on rotational strategy timing, indicating near-term weak sentiment but mid-term strength. It details specific institutional trading strategies, including position trading, momentum breakout, and risk hedging, with entry zones, target prices, and stop losses. The analysis also provides multi-timeframe signal analysis, showing varying signal strengths, support, and resistance levels for different time horizons.
Surgery Partners faces earnings test amid margin, volume concerns By Investing.com
Surgery Partners Inc. is set to report its first-quarter results, with analysts anticipating a loss of 12 cents per share on revenue of $797.32 million, a significant decline from the previous quarter. Investors are focusing on volume trends, margin performance given prior compression, and capital allocation strategies due to activist investor pressure. The report will be crucial in determining if the company's recovery efforts are yielding positive results amidst ongoing operational challenges.
Surgery Partners faces earnings test amid margin, volume concerns
Surgery Partners (NASDAQ:SGRY) is set to report its first-quarter earnings, with analysts expecting a loss of 12 cents per share on revenue of $797.32 million. The report will assess whether the company is recovering from operational challenges faced in late 2025, particularly concerning volumes and margin performance. Investors will also scrutinize capital allocation decisions, especially in light of activist investor pressure.
UBS Group AG Has $120.57 Million Stake in Surgery Partners, Inc. $SGRY
UBS Group AG significantly increased its stake in Surgery Partners, Inc. (NASDAQ:SGRY) in the fourth quarter, now owning 6.03% of the company, valued at $120.57 million. Despite this institutional confidence and a new $200 million share buyback program indicating potential undervaluation, company insiders have recently sold a substantial number of shares. Analysts currently rate Surgery Partners with a "Moderate Buy" and an average price target of $22.00.
Assessing Surgery Partners (SGRY) Valuation As King Street Boosts Stake And Higher Acuity Cases Gain Traction
Surgery Partners (SGRY) is attracting attention after King Street Capital increased its stake, coinciding with the company's expansion into higher acuity outpatient procedures. Despite a 73% 5-year share price loss, SGRY is trading at an approximate 33% discount to analyst targets and has an undervalued fair value of $18.80, driven by the migration of high-acuity surgical procedures to outpatient settings. The narrative suggests growth through investments in robotics and facilities, though risks like interest costs and slower acquisitions could impact margins.
Surgery Partners, Inc. (NASDAQ:SGRY) Short Interest Up 13.2% in April
Surgery Partners, Inc. (NASDAQ:SGRY) experienced a significant 13.2% increase in short interest in April, reaching 15,839,348 shares, indicating heightened bearish sentiment. While institutional investors like Millennium Management and Invesco Ltd. have increased their positions, company insiders, including CEO Jason Eric Evans, have sold shares. Analysts maintain a "Moderate Buy" rating with an average price target of $22.00, despite the company missing EPS estimates but beating revenue expectations in its latest quarter.
Assessing Surgery Partners (SGRY) Valuation As King Street Boosts Stake And Higher Acuity Cases Gain Traction
Surgery Partners (SGRY) is attracting attention after King Street Capital increased its stake, coinciding with the company's focus on higher acuity outpatient procedures. Despite a 73% five-year loss, SGRY shares are trading at a significant discount to analyst targets and intrinsic value, presenting a potential undervaluation. The company's strategy to capitalize on the migration of high-acuity surgeries to outpatient settings is seen as a key driver for long-term growth, though risks like interest costs and acquisition pace could impact its trajectory.
King Street Capital Increases Stake in Surgery Partners Inc
King Street Capital has significantly increased its investment in Surgery Partners Inc. (NASDAQ:SGRY), bringing its holdings to over 10.2 million shares by the end of Q4 2025. This expansion reflects growing institutional interest as Surgery Partners focuses on high-acuity medical services and aims to consolidate the fragmented ambulatory surgery center market. Analysts believe this strategy will drive long-term EBITDA growth despite conservative 2026 financial guidance.
Surgery Partners (SGRY) Projected to Post Quarterly Earnings on Tuesday
Surgery Partners (SGRY) is projected to announce its Q1 2026 earnings before market open on Tuesday, May 5th, with analysts forecasting a loss of $0.15 per share and revenue of approximately $797.7 million. Despite missing EPS estimates in the prior quarter, the company's revenue increased by 2.4% year-over-year, and analysts maintain a "Moderate Buy" rating with a consensus target price of $22.00 against a current share price of around $14.44. The board has also authorized a $200 million share buyback program.
Surgery Partners Inc. (SGRY): Billionaire Brian Higgins Likes This Stock
Billionaire Brian Higgins' fund, King Street Capital, has significantly increased its stake in Surgery Partners, Inc. (SGRY), holding over 10.2 million shares by Q4 2025. This investment reflects a positive view on SGRY's strategic shift towards high-acuity outpatient procedures despite measured 2026 guidance. The company is seen as well-positioned to consolidate the fragmented ambulatory surgery center market.
Does Surgery Partners (SGRY) Guidance Cut Reveal a Deeper Shift in Case-Mix Strategy?
Surgery Partners (SGRY) recently cut its earnings guidance due to slower surgical case growth, a less favorable payer mix, and reimbursement pressures. Despite these operational challenges, the company is focusing on higher-acuity procedures and robotics investments to reshape its case mix. This guidance cut challenges the near-term earnings recovery narrative and highlights the risk of weaker cash generation impacting growth funding and debt management.
Surgery Partners (NASDAQ: SGRY) details 2026 meeting, board and pay votes
Surgery Partners (NASDAQ: SGRY) has detailed its 2026 virtual annual meeting scheduled for June 5, 2026, where stockholders will vote on the election of three Class II directors, an advisory say-on-pay resolution, and the ratification of Ernst & Young LLP as its independent auditor. The company reported 2025 revenue of $3.31 billion, a 6.2% increase, and Adjusted EBITDA of $526.2 million, up 3.5%, but experienced a net loss of $77.9 million, leading to no annual cash bonuses for named executive officers. The Board unanimously recommends voting "FOR" all management proposals, and stockholders can participate and vote online or via proxy.
[ARS] Surgery Partners, Inc. SEC Filing
This article announces an ARS SEC filing by Surgery Partners, Inc. (SGRY) filed on April 23, 2026. The filing is an ARS type, indicating a specific regulatory disclosure, and is available as a PDF document on SEC EDGAR. The article also provides an overview of SGRY's stock performance, recent news, and other SEC filings.
Does Surgery Partners (SGRY) Guidance Cut Reveal a Deeper Shift in Case-Mix Strategy?
Surgery Partners recently lowered its earnings guidance due to slower surgical case growth, an unfavorable payer mix, and reimbursement pressures, despite its continued focus on higher-acuity procedures and robotics investments. This guidance cut challenges the near-term earnings recovery narrative and highlights the risk of weaker cash generation impacting debt management and growth funding. The article also notes a limited capital deployment from a US$200 million share repurchase authorization, making it a key element to monitor alongside M&A and de novo spending.
Surgery Partners (NASDAQ:SGRY) Share Price Crosses Below 200 Day Moving Average - What's Next?
Surgery Partners (NASDAQ:SGRY) saw its stock price fall below its 200-day moving average to $14.58. The company missed Q4 earnings expectations, reporting wider losses per share than anticipated, though revenue slightly exceeded forecasts. Despite a "Moderate Buy" consensus from analysts and a $200 million stock buyback authorization, insider selling indicates some caution.
AUNA vs. SGRY: Which Hospital Stock Looks More Attractive Now?
This article compares Auna S.A. (AUNA) and Surgery Partners (SGRY), two healthcare service providers that generate revenue from hospital networks. Auna, with operations in Mexico, Peru, and Colombia, focuses on high-complexity diseases and shows strong regional performance and financial flexibility. Surgery Partners, concentrating on non-emergency surgical procedures, experienced a challenging fourth quarter in 2025 due to delayed capital deployment and unfavorable payer mix, leading to a weaker price performance and premium valuation compared to Auna.
Allstate Sues Surgery Partners Over Alleged Florida Billing Scheme
Allstate has filed a lawsuit against Surgery Partners, Inc. and several Florida-based surgery centers, alleging a multimillion-dollar billing scheme for exaggerated or unperformed medical procedures. The insurer claims the defendants billed for medically unnecessary or fabricated services following automobile accidents, impacting Personal Injury Protection payouts. Allstate named the parent company, Surgery Partners, Inc., as a defendant and is seeking triple damages under federal racketeering laws.
Allstate sues Surgery Partners, alleges Florida surgery centers ran billing scheme
Allstate has filed a lawsuit against Surgery Partners, Inc. and several Florida surgery centers, accusing them of a multi-million-dollar billing scheme. The insurer alleges that these centers billed for procedures that were exaggerated, medically unnecessary, or never performed, draining auto insurance payouts. Allstate is seeking triple damages under federal racketeering statutes and a court order to stop paying pending claims and bar future billing to its policyholders.
Benchmark Maintains Surgery Partners (SGRY) Buy Recommendation
Benchmark has reiterated its Buy recommendation for Surgery Partners (SGRY). The article doesn't provide further details on why Benchmark maintains this rating, as only the title and a placeholder content "MSN" were given.
Surgery Partners Q1 Earnings: A Test of Resilience Amid Growth
Surgery Partners (NASDAQ:SGRY) is set to release its Q1 2026 earnings, a critical report following a challenging Q4 2025 marked by unexpected headwinds and margin compression despite revenue growth. Investors will be looking for signs of recovery in same-facility revenues and case volume, as well as management's strategies to navigate industry pressures like labor costs and high debt, while continuing its growth-by-acquisition model. The report will assess if recent challenges were temporary or indicate a more persistent trend for the short-stay surgical sector leader.
Envista, Baxter, Surgery Partners, Charles River Laboratories, and Repligen Stocks Trade Up, What You Need To Know
Stocks for Envista, Baxter, Surgery Partners, Charles River Laboratories, and Repligen saw increases after a global logistics and energy cost cooling, indicated by the reopening of the Strait of Hormuz. Lower oil prices directly reduce operating and shipping costs for healthcare providers and medical device manufacturers, improving their profit margins. This "risk-on" sentiment also benefits high-growth biotech and pharmaceutical companies, as reduced market volatility encourages investment in R&D and clinical trials, with the global economy stabilizing an upward trend for elective procedures and pharmaceutical demand.
Envista, Baxter, Surgery Partners, Charles River Laboratories, and Repligen Stocks Trade Up, What You Need To Know
Several healthcare and biotech stocks, including Envista, Baxter, Surgery Partners, Charles River Laboratories, and Repligen, observed a jump in their stock prices. This surge is attributed to the reopening of the Strait of Hormuz, which is expected to lower global logistics and energy costs, benefiting the healthcare sector by reducing operational and shipping expenses. Additionally, a resulting "risk-on" sentiment is driving investment back into high-growth biotech and pharmaceutical companies, fostering a more positive outlook for the sector's earnings and R&D.
Surgery Partners, Inc. Announces First Quarter 2026 Earnings Release Date and Conference Call Details
Surgery Partners, Inc. (NASDAQ: SGRY) will release its first quarter 2026 financial results before the market opens on Tuesday, May 5, 2026. The company will host a conference call at 8:30 a.m. (Eastern Time) on the same day to discuss the results. Interested parties can access the call via phone or a simultaneous webcast on the company's Investor Relations website.
Surgery Partners posts Q1 results May 5, webcast at 8:30 ET
Surgery Partners (NASDAQ:SGRY) announced it will release its first quarter 2026 results before market open on Tuesday, May 5, 2026, followed by a conference call and webcast at 8:30 a.m. ET. The company has provided dial-in numbers and replay details, noting that financial and material information is routinely posted on its investor relations website. This announcement aligns with Surgery Partners' consistent communication cadence for investor engagement.
Surgery Partners to Announce First Quarter 2026 Financial Results on May 5, 2026
Surgery Partners, Inc. will release its first quarter 2026 financial results before market open on May 5, 2026, followed by a conference call at 8:30 a.m. Eastern Time. The company, a leading provider of short-stay surgical facilities with over 200 locations, will offer access to the call via dial-in numbers and a live webcast. This announcement aims to provide transparency and inform stakeholders about the company's financial performance.
